Medication – ALGECIA – PREGABALIN 75mg, 150mg, 300mg,

ALGECIA – PREGABALIN 75mg, 150mg, 300mg, – Hard Capsules

 Pregabalin is an antiepileptic used as an adjunct in the treatment of partial seizures. It is also used in the treatment of generalized anxiety disorder, neuropathic pain and fibromyalgia. Pregabalin has also demonstrated analgesic activity. It is structurally related to the inhibitory CNS neurotransmitter -aminobutyric acid (GABA). Although developed as a structural analog of GABA, pregabalin does not bind directly to GABAA, GABAB or benzodiazepine receptors. It binds with high affinity to the α2-δ site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues. Although the exact mechanism of action of pregabalin has not been elucidated, binding to the α2-δ subunit may be involved in pregabalin’s analgesic and anticonvulsant effects. In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, including glutamate, norepinephrine, calcitonin gene-related peptide and substance P, possibly by modulation of calcium channel function. 

Pregabalin is rapidly absorbed after oral doses and peak plasma concentrations occur within 1.5 hours with an oral bioavailability of about 90%. The rate but not the extent of absorption is reduced if given with food. It is not bound to plasma proteins and undergoes negligible metabolism. About 90 – 98% is excreted in the urine as unchanged drug. The mean elimination half-life is about 6 – 6.3 hours. Pregabalin is removed by haemodialysis.  

Made in Greece PIL_Algecia_caps_10-6-2019